EN / CN

News

Current Position: Home ››  News

08

2026Year10Month

Breaking News | Fondaparinux Sodium API Gains Marketing Authorization!

Newland Pharma has recently received approval from the National Medical Products Administration (NMPA) for its Fondaparinux Sodium API.
[View Details]

02

2026Year10Month

Milan Awaits Us in October | Newland Pharmaceutical Welcomes You to CPHI Worldwide 2026

Whether you are seeking a trusted API and intermediate manufacturing partner or discussing a specific project, we invite you to visit Booth H3K98.
[View Details]

01

2026Year10Month

Grand Celebration of the Nation, Joy Shared by All | The 77th Anniversary of the Founding of the People's Republic of China

Grand Celebration of the Nation, Joy Shared by All | The 77th Anniversary of the Founding of the People's Republic of China
[View Details]

21

2026Year09Month

Newland Pharmaceutical Awarded CEP Certificate for Moxifloxacin Hydrochloride API

Recently, our company received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP Certificate) for Moxifloxacin Hydrochloride API, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
[View Details]

23

2026Year07Month

Amlodipine Besylate API Approved for Marketing!

Newland Pharmaceutical's Amlodipine Besylate API has received NMPA marketing approval, marking another step forward in the company's cardiovascular API portfolio.
[View Details]
Total56Items   1 / 12Page  Per Page5Items  First Page  Previous  Next  Last Page